France· FR:62292771
POTELIGEO 4 mg/mL, solution à diluer pour perfusion
A medicinal product containing mogamulizumab, registered in France by KYOWA KIRIN HOLDINGS (PAYS-BAS).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MOGAMULIZUMAB
- Manufacturer
- KYOWA KIRIN HOLDINGS (PAYS-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009302249601 flacon en verre de 5 mL
- cip1334009550604061 flacon en verre de 5 mL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mogamulizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsPoteligeo 4 mg/mL concentratie voor oplossing voor infusieKyowa Kirin Limited
- FinlandPoteligeoOrifarm Oy
- CanadaPOTELIGEOKYOWA KIRIN, INC.
- SwitzerlandPoteligeo 4 mg/ml, Konzentrat zur Herstellung einer InfusionslösungKyowa Kirin Sàrl
- CzechiaPOTELIGEOKyowa Kirin Holdings B.V., Hoofddorp
- SpainPOTELIGEO 4 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONKyowa Kirin Holdings B.V.
- United KingdomPoteligeo 20mg/5ml concentrate for solution for infusion vialsKyowa Kirin Ltd
- IrelandPOTELIGEO 4 mg/mL concentrate for solution for infusionKyowa Kirin Holdings B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Poteligeo
- Liechtenstein · Poteligeo
- Norway · Poteligeo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/68938433-c6cf-415d-961d-c50e0b1831a1 GET /v1/drugs/68938433-c6cf-415d-961d-c50e0b1831a1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62292771",
"date_amm": "2018-11-22",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/18/1335",
"substance": "MOGAMULIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about mogamulizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.